Home / Going-concern warnings / ATOSSA THERAPEUTICS, INC.
Filed 2026-03-25 路 Form 10-K 路 Accession 0001193125-26-124396 nano
Price before filing: $5.51 (2026-03-24 close, split/dividend-adjusted)
Market cap at flag: $46.7M (2026-03-25) 路 Latest: $25.9M (2026-10-16)
| Window | ATOS | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +3.4% | +9.3% | -5.9% | 2026-04-24 |
| 90 days | -65.5% | +12.6% | -78.1% | 2026-06-23 |
| 180 days | -59.2% | +19.0% | -78.2% | 2026-09-21 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These conditions raise substantial doubt as to our ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-K (period 2025-12-31)
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.